Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.
Ora Banda Mining reports a robust December quarter, boosting cash reserves to $57.8 million and advancing underground operations at Riverina and Sand King towards a 150koz production target in FY26.